Latebreakers: FDA drug safety bill one step closer to reality
Like the Senate, the House has passed a bill that would give the FDA more authority to ensure drug safety by requiring manufacturers to conduct postmarketing surveillance studies; demand more user fees; and other measures.
Like the Senate, the House has passed a bill that would give the FDA more authority to ensure drug safety by requiring manufacturers to conduct postmarketing surveillance studies; demand more user fees; and other measures. Since H.R. 2900 contains some provisions that are different from S. 1082, with the House version considered the stronger one, a conference committee will now have to come up with a new bill that both houses can approve before it is sent to the President for signature.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
